Immunocore HoldingsIMCR
Recorded

Immunocore Holdings UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Dina ElmonshedBiotech Analyst

Hello, everyone. My name is Dina Al-Manchet, one of the biotech analysts here at UBS, and I am excited and pleased to welcome Travis Coy, Chief Financial Officer of Immunocore. I am excited for us to get started on this. Maybe we can start with a couple of questions around the commercial business for KIMMTRAK.

Dina ElmonshedBiotech Analyst

Maybe just, we are probably in our fourth year of launch now, given pretty peak penetration levels in especially OUS market and maybe 70% in the U.S., nearly there. So, maybe just thinking about where are there remaining growth drivers, particularly in the community setting, both in the U.S. and OUS, and where do you see KIMMTRAK from here in the outer years?

Travis CoyCFO

Yeah. No, thanks, Dina. First of all, thank you for having me.

Travis CoyCFO

Of course. Appreciate you having us.

Travis CoyCFO

All good questions on KIMMTRAK. We are really pleased that KIMMTRAK has become the standard of care across all major markets. You are elaborating to some of the penetration levels we have. We are at 70% plus penetration across all markets. As we look at the growth, naturally in this part of the product's life cycle, we are seeing growth begin to moderate. It is a good thing, right? We did a good job on launch, right?

Dina ElmonshedBiotech Analyst

You launched very quickly. Yeah.

Travis CoyCFO

We still see opportunities for growth. There are two different aspects. There is the U.S. and the OUS. From a U.S. perspective, growth is centered and focused on penetrating further into that community setting, continue to increase patient access in that community setting. OUS, our growth mainly comes from new launches. We are 80% to 90% penetrated in some of those markets, so new launches are really where we see the growth. Again, it is increasing that patient access. We also see some growth OUS from increasing duration of therapy. Some of the markets where we have more recently launched, that duration of therapy is still ticking up to where it already is in established markets.

Dina ElmonshedBiotech Analyst

Okay. That makes sense. What is the duration of therapy now? I think the last time we talked about this, maybe around 14 months. What is it looking like now in nearly 2027?

Travis CoyCFO

Yeah. So, I'll mention, we are five years on the market now.

Travis CoyCFO

Yes By the way, that's okay.

Travis CoyCFO

So, as we look at the duration of therapy, in the U.S., it's mostly stabilized.

Travis CoyCFO

Okay. I'd say it's fair to say across the major markets where we've been launched.

Travis CoyCFO

Yep Four or five years.

Travis CoyCFO

Yep we mostly see the duration of therapy around 14 months.

Travis CoyCFO

Okay. What is remarkable about that is, in the clinical setting, we saw around 10 to 11 months.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day